<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409994</url>
  </required_header>
  <id_info>
    <org_study_id>04-16</org_study_id>
    <nct_id>NCT00409994</nct_id>
  </id_info>
  <brief_title>Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer</brief_title>
  <official_title>A Clinical Trial Testing Rapamycin, an mTOR-inhibitor, in Combination With Preoperative Radiotherapy in Operable Rectum Cancer: a Phase I and Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Ziekenhuis Maastricht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigating the safety and the activity of Rapamycin, administered before and during
      preoperative radiotherapy in patients with an operable colorectal carcinoma. The phase I dose
      escalation study will be performed in three steps (2, 4 and 6 mg). Patients entered in phase
      II will follow the same tolerable treatment regimen as patients in phase I study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment regimen Phase I A daily dose of Rapamycin will be taken during 13 days. At step 1 a
      dose of 2 mg will be given once a day; at step 2 a dose of 4 mg will be given once a day; at
      step 3 a dose of 6 mg will be given once a day.

      Preoperative radiotherapy (5x 5 Gy) will be administered at day 8-12, followed by TME-surgery
      at day 15.

      Phase II A daily dose of 6 mg Rapamycin will be taken for 14 days (unless the optimal dose
      found in the phase I study is lower).

      Preoperative radiotherapy (5x 5 Gy) will be administered at day 9-15, followed by TME-surgery
      7-8 weeks post RT.

      Sample size Phase I dose-escalation study Minimum 3 eligible patients per step, maximum 6
      eligible patients per step. Phase II A total of 47 patients will be entered in this part of
      the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Incidence of severe postoperative complications (grade IV or grade V),</measure>
    <time_frame>within the first 6 weeks after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>assessed according to CTCv3.0</measure>
    <time_frame>within the first 6 weeks after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Tumour blood flow assessed CT-PET + CTp</measure>
    <time_frame>day 64</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I:Incidence of other acute toxicity, assessed according to CTCv 3.0</measure>
    <time_frame>within the first 6 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation status of mTor related and dependent molecules in the tumour</measure>
    <time_frame>within the first 6 weeks after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II:Maximum standardised Uptake Value (SUV) of 18F-FDG, assessed bij PET-CT-scan</measure>
    <time_frame>day 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II:Incidence of acute side effects of rapamycin, assessed according to CTCv 4.0</measure>
    <time_frame>day 8, 15, 22, 36, 50 and 64</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Rectum Cancer</condition>
  <arm_group>
    <arm_group_label>Rapamycine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rapamycine 6 mg dd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin</intervention_name>
    <description>dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days</description>
    <arm_group_label>Rapamycine</arm_group_label>
    <other_name>Sirolimus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven rectum cancer

          -  UICC TNM I-III

          -  WHO performance status 0-2

          -  Less than 10% weight loss the last 6 months

          -  No recent (&lt; 3 months) severe cardiac disease

          -  Normal serum bilirubin and serum creatinin

        Exclusion Criteria:

          -  Concurrent chemotherapy with radiation

          -  History of prior pelvis radiotherapy

          -  Recent (&lt;3 months) myocardial infarction

          -  Uncontrolled infectious disease

          -  Concurrent medication known as inhibitors of CYP3A4 susceptible to increase Rapamycin
             blood concentrations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeroen Buijsen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht Radiation Oncology</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2006</study_first_submitted>
  <study_first_submitted_qc>December 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2006</study_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>M-tor inhibitor</keyword>
  <keyword>Rapamycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

